
BioMérieux is a French multinational company founded in 1963 by Marcel Mérieux. It's headquartered in Marcy-l'Étoile, France.
BioMérieux specializes in in vitro diagnostics, offering a wide range of solutions for clinical and industrial applications. Their products include microbiology, virology, and molecular biology testing systems.
The company has a strong presence in over 150 countries worldwide, with a global network of subsidiaries and distributors. This extensive reach allows BioMérieux to provide its products and services to a diverse range of customers.
BioMérieux's commitment to innovation and quality has earned it a reputation as a leader in the in vitro diagnostics industry.
For more insights, see: Lukens Steel Company
Historique
In 1963, BioMérieux was founded by Marianne and Charles Mérieux in Marcy-l'Étoile, France.
The company's early days were marked by a focus on developing vaccines and serums for infectious diseases.
Marianne Mérieux played a crucial role in the company's growth, serving as its president until her death in 2002.
Charles Mérieux was a renowned scientist who made significant contributions to the field of virology.
Readers also liked: Orange France Company
BioMérieux's first product was a diagnostic kit for tuberculosis, which was a major public health concern at the time.
The company's innovative approach to diagnostics was driven by its commitment to improving patient outcomes.
Marianne Mérieux was also a pioneer in the field of microbiology, and her work laid the foundation for BioMérieux's future success.
BioMérieux's early success was fueled by its ability to develop and commercialize innovative diagnostic solutions.
The company's products quickly gained recognition for their accuracy and reliability.
By the 1980s, BioMérieux had established itself as a leading player in the global diagnostics market.
France Presence
BioMérieux has a strong presence in France. The company is a French pharmaceutical enterprise with its headquarters in France.
BioMérieux is listed on the Euronext stock exchange and is part of the CAC Next 20 and Euronext 100 indices. This indicates its significant size and influence in the French market.
Here are some key locations for BioMérieux in France:
- 376, chemin de l’Orme, 69280 Marcy l’Etoile
This information suggests that BioMérieux has a significant presence in France, with a major location in Marcy l'Etoile.
In France

In France, BioMérieux exercises lobbying activities for an amount not exceeding 500,000 euros in 2024.
The company is a listed enterprise on the Euronext, a French pharmaceutical company with its headquarters in France.
BioMérieux is also part of the CAC Next 20 and Euronext 100, indicating its significant presence in the French market.
Here are some key facts about BioMérieux's presence in France:
- Company listed on Euronext
- Headquartered in France
- Part of CAC Next 20
- Part of Euronext 100
Worldwide
bioMérieux has a significant presence worldwide, with offices and subsidiaries in many countries.
bioMérieux Algeria is located in Dely Ibrahim, Algeria, while bioMérieux Benelux SA/NV is based in Brussels, Belgium.
bioMérieux has a strong presence in Europe, with subsidiaries in Czechia, Denmark, Finland, Hungary, Poland, and Türkiye.
bioMérieux CZ s.r.o is located in Prague, Czechia.
bioMérieux also has a significant presence in Asia, with subsidiaries in China, India, Indonesia, Japan, Malaysia, Singapore, South Korea, and Thailand.
bioMérieux China Limited has offices in Beijing, Chengdu, and Guangzhou, China.
bioMérieux has subsidiaries in South America, including bioMérieux Argentina in Buenos Aires, Argentina, and bioMérieux Colombia SAS in Bogotá, Colombia.
bioMérieux P/L is located in Sydney, Australia.
bioMérieux has a global reach, with subsidiaries in the Middle East and Africa, including bioMérieux Middle East FZ-LLC in Dubai, United Arab Emirates.
Financial Performance
bioMérieux's financial performance is quite impressive, with revenues reaching €3.1 billion as of 2020.
The company's sales are largely driven by international markets, with a staggering 93% of sales occurring outside France.
bioMérieux's presence in the global market is reflected in its inclusion in the CAC Next 20, a prestigious index of French companies.
The company's financial standing is also a testament to its stability and growth, with a long history dating back to 1963 when it was founded by the Mérieux family.
bioMérieux's listing on Euronext Paris is a further indication of its solid financial foundation.
Here's a quick rundown of bioMérieux's key financial indicators:
Investment and Valuation
The market capitalization of bioMérieux has fluctuated over the years, ranging from 11.7 billion to 21.81 billion euros.
In 2025, the price-to-earnings ratio (PER) is expected to be around 28.4x, while in 2026, it's anticipated to be approximately 23.4x.
The company's valuation can be compared to its market capitalization, with a value of 13.07 billion euros in 2025.
The value-to-capitalization (VE/CA) ratio is also significant, standing at around 3.13x in 2025 and 2.87x in 2026.
bioMérieux's stock has a floating rate of 36.04%, indicating a relatively high level of volatility.
The expected dividend yield for 2025 is 0.85%, while for 2026, it's projected to be around 1.03%.
Here's a summary of bioMérieux's market capitalization and valuation metrics:
The expected dividend yield for 2025 is 0.85%, while for 2026, it's projected to be around 1.03%.
Recent News and Updates
bioMérieux has seen a positive trend in recent news, with a "tendence est haussière" (upward trend) reported.
On October 22, CIC Market Solutions upgraded its opinion on bioMérieux.
Invest Securities downgraded its recommendation on bioMérieux, no longer considering it a buy, on September 5.
bioMérieux announced a collaboration with Altesa BioSciences for a phase 2B clinical trial on BPCO on September 9.
Here are some key dates related to bioMérieux's recent news:
UBS upgraded its target price for bioMérieux on September 11.
Recommandations des Analystes
BioMérieux has received various analyst recommendations.
CIC Market Solutions upgraded its opinion on BioMérieux on October 22nd.
On September 11th, UBS raised its target price for BioMérieux.
Invest Securities changed its recommendation on BioMérieux to "n'est plus à l'achat" on September 5th.
Here's a summary of the analyst recommendations:
Leadership and Management
At BioMérieux, leadership is in good hands. Pierre Boulud, the CEO, has been leading the company since July 1, 2023, at the age of 53.
The company's management team includes Guillaume Bouhours, who has been the Director Financier/CFO since March 1, 2018, at 49 years old. Charles Cooper, the CTO, joined the team on January 2, 2024, but his age is not publicly disclosed.
Jean-Luc Bélingard, a seasoned leader, has been the Chairman of the Board since January 1, 2014, at the age of 76. Alexandre Mérieux has also been a Chairman of the Board since December 15, 2017, at 51 years old.
Philippe Archinard has been a Director/Membre du Conseil since January 1, 2005, at 64 years old.
Company Profile
BioMérieux is a global company that specializes in the development of in vitro diagnostic solutions. Founded in 1963, it has been a leader in the field for over 50 years.
BioMérieux was founded by Marcel Mérieux, a French scientist who was passionate about microbiology and diagnostics. He started the company in a small laboratory in Marcy-l'Étoile, France.
The company's early focus was on developing diagnostic kits for bacterial infections, which was a game-changer in the field of microbiology. This innovative approach helped to improve patient outcomes and saved countless lives.
BioMérieux's headquarters are still located in Marcy-l'Étoile, France, where the company's commitment to innovation and quality is still evident today.
Expert Analysis and Opinions
BioMérieux is off to a great start, with promising semi-annual results that confirm its market appeal.
Their semi-annual results are a testament to the company's ability to attract and retain customers.
The company is expanding its presence, which is a key factor in its success.
BioMérieux's growth is a reflection of its strong market position and customer loyalty.
The company's results show a clear trend of steady growth and increasing market share.
BioMérieux's success can be attributed to its innovative products and services that meet the evolving needs of the market.
Their ability to adapt to changing market conditions has helped the company stay ahead of the competition.
BioMérieux's expansion plans are a key factor in its continued growth and success.
The company's commitment to innovation and customer satisfaction is a winning formula that is paying off.
Product Line
BioMérieux has a comprehensive product line that caters to various needs in microbiology and diagnostics. Their product line includes a wide range of solutions for clinical and industrial applications.
Their solutions for clinical applications include the VITEK system, which provides rapid and accurate identification of microorganisms. This system has been widely adopted in hospitals and laboratories around the world.
BioMérieux's industrial solutions include the Bacillus cereus detection kit, which helps detect contamination in food and pharmaceutical products. This kit is designed to be user-friendly and provide reliable results.
Their product line also includes the API system, which is a microorganism identification system used in laboratories and hospitals.
Vitek Ms Prime

Vitek Ms Prime is a cutting-edge system that allows for precise identification of each species using MALDI-TOF automated mass spectrometry.
This system is a new generation of automated mass spectrometry, making it a valuable addition to any laboratory.
With Vitek Ms Prime, you can rely on accurate results to inform your decisions and take action against infections.
It's designed to be efficient, providing results in a timely manner, just like the Vitek Reveal system, which offers rapid AST results for effective sepsis management.
By using Vitek Ms Prime, you can make informed decisions in just a couple of hours, similar to the GENE UP TYPER system, which can identify the cause of contamination and prevent its spread in a short amount of time.
Vidas Kube™
The VIDAS KUBE is a game-changer in laboratory solutions.
It's designed to preserve the advantages of the VIDAS solution that labs love, while incorporating cutting-edge technology.
VIDAS KUBE is an automated immuno-assay solution that's both flexible and cost-effective.
System Biofire Spotfire
The System Biofire Spotfire is a cutting-edge diagnostic tool that offers rapid and actionable results at the point of care. It's designed for bedside testing, making it a game-changer for healthcare professionals.
This system is the latest advancement from bioMérieux in molecular disease diagnosis. The Biofire Spotfire system provides quick and reliable results on-site.
It's perfect for situations where time is of the essence, and every minute counts. The system's speed and accuracy can be a lifesaver in emergency situations.
Detection and Testing
BioMérieux offers a range of innovative solutions for detection and testing.
Their automated detection system, VIDAS KUBE, simplifies the laboratory process, making it more productive, precise, and cutting-edge.
Nous Contribuons à Améliorer la Santé
We've been contributing to improving health worldwide since 1963, when the Mérieux family first envisioned a better future for health. Our commitment to public health is the thread that runs through everything we do.
Our dedication to serving the public health is what drives us forward. We're proud to be carrying on the legacy of the Mérieux family.
The Mérieux family's values of respect, responsibility, transparency, and sharing are at the heart of everything we do. These values have guided us since the beginning.
Recommended read: Happy Family (food Company)
Frequently Asked Questions
Qui sont les concurrents de bioMérieux ?
Les principaux concurrents de bioMérieux sont des sociétés telles que IBL International GmbH, Argené, et ALSACHIM, qui offrent des solutions de diagnostic et de biotechnologie. Ces entreprises concurrentes opèrent dans le même secteur que bioMérieux et proposent des produits et services similaires.
Quels sont les produits phares de bioMérieux ?
Les produits phares de bioMérieux incluent l'AIR IDEAL 3P, API, BACT/ALERT, BACT/ALERT VIRTUO, BIOBALL Custom Services et BIOBALL Souches calibrées. Ces solutions innovantes répondent aux besoins de l'analyse de l'air, de l'identification microbienne et de la détection microbienne rapide
Pourquoi travailler chez bioMérieux ?
Travailler chez bioMérieux signifie contribuer à l'amélioration de la santé publique à travers des missions essentielles dans la lutte contre les maladies infectieuses. Rejoignez notre équipe pour faire une différence positive dans le monde.
Featured Images: pexels.com
